Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Expands By 223.9%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 29,800 shares, a growth of 223.9% from the June 30th total of 9,200 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 24,300 shares, the days-to-cover ratio is currently 1.2 days.

Barinthus Biotherapeutics Trading Down 6.2 %

Barinthus Biotherapeutics stock traded down $0.09 during midday trading on Friday, reaching $1.37. The stock had a trading volume of 24,533 shares, compared to its average volume of 26,262. Barinthus Biotherapeutics has a 12 month low of $1.21 and a 12 month high of $5.10. The firm’s 50-day moving average price is $1.69 and its 200 day moving average price is $2.34.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its earnings results on Monday, May 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.24. As a group, research analysts anticipate that Barinthus Biotherapeutics will post -1.9 EPS for the current year.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Catalina Capital Group LLC purchased a new stake in shares of Barinthus Biotherapeutics in the second quarter worth $25,000. Ipswich Investment Management Co. Inc. purchased a new stake in shares of Barinthus Biotherapeutics in the second quarter worth $32,000. BlueCrest Capital Management Ltd purchased a new stake in Barinthus Biotherapeutics during the first quarter valued at about $1,292,000. DC Funds LP bought a new stake in Barinthus Biotherapeutics during the first quarter worth about $1,528,000. Finally, M&G Plc purchased a new position in shares of Barinthus Biotherapeutics in the 2nd quarter worth about $7,276,000. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Barinthus Biotherapeutics in a research note on Friday, June 7th. William Blair reissued an “outperform” rating on shares of Barinthus Biotherapeutics in a research note on Thursday, June 13th. Finally, Barclays reduced their price objective on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating for the company in a research report on Thursday, June 13th.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.